A Therapeutic Targeting Identification from Microarray Data and Quantitative Network Analysis

Personalized therapy is “the right drug for the right patient at the right time”. Here we reported a case of personalized therapy using gene expression signature (GES) related drug discovery to treat a patient with drug-resistant metastases from breast-tumor. Methods: After mRNA obtained from metastatic liver tissue was performed by microarray, GES of genomic profiles were uncovered by bioinformatics tool and targeting drugs related with GES were mined by drug-bank. Several targeting-drugs approved by FDA were selected to treat the patient. Results: 1198 genes were uncovered for the higher expression by two-fold to compare normal liver specimens in which 10 of mined genes were identified as set-1 GES for metastasis and 16 of genes were uncovered as set-2 directly for primary breast tumor. Drug-bank platform were used to discover drugs for target set-1/2 genes. Eventually, medropxyoprogesterone (MPA) targeting set-I gene and doxorubicin targeting set-2 gene were selected for the patient because the two drugs have already been approved by FDA. After doxorubicin and MPA were administered, patient's metastatic-tumor showed complete response. Conclusions: We not only analyze genomic expression profiles but also discover sensitive compounds for drug-resistant tumor. We successfully select drugs approved by FDA to treat the patient.